Home > Healthcare > Pharmaceuticals > Finished Drug Form > Opioid Use Disorder Market

Opioid Use Disorder Market Trends

Report ID: GMI5838
Published Date: May 2023
Report Format: PDF

Download Free Sample

Opioid Use Disorder Market Trends

Opioids are a group of painkillers that are used to relax muscles, reduce pain, and relieve stress. The chronic, relapsing brain illness known as opioid usage disorder is characterized by excessive opioid seeking and use despite its side effects. It is regarded as a brain condition because it involves functional changes to brain circuits related to motivation, stress, self-control, and decision-making, and because those changes may endure for a considerable amount of time after drug use has stopped. An overwhelming desire to consume opioids, increased opioid tolerance, and withdrawal symptoms after cessation are all symptoms of opioid use disorder.

The increasing opioid prescribers, increasing awareness about OUD among population, increasing government initiatives to diagnose and treat OUD, and rise in product approvals for OUD treatment drugs anticipated to fuel the market expansion. For instance, in May 2020, Indivior PLC, a pharmaceutical company in the U.S., announced the approval of Subutex from Swedish Medical Products Agency (MPA). Subutex is a prolonged release solution available in the form of injection- 100 and 300mg for substitution treatment of opioid dependence in adults and adolescents over 16 years of age.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market for opioid use disorder amassed USD 2.8 billion in 2022 and is set to grow at a 10.6% CAGR from 2023 to 2032 owing to the rise in drug approvals for the treatment of opioid use disorder and increasing opioid addiction cases in developed counties.

The buprenorphine segment is estimated to register significant growth from 2023 to 2032 owing to the increasing use of buprenorphine as an effective option to improve the quality of life for patients undergoing addiction treatment.

The North America opioid use disorder (OUD) industry accounted for more than 49.3% of the global industry revenue in 2022 and is poised to depict robust growth driven by the increasing number of product launches for the treatment of opioid use disorder and a well-established opioid industry across the region.

The major players operating in the market are Alkermes, Inc., Indivior PLC, BioDelivery Sciences International, Inc., Orexo US, Inc., Titan Pharmaceuticals, Inc., Omeros Corporation, Camurus, Hikma Pharmaceuticals PLC, AstraZeneca plc, and Viatris Inc.